Purified Bacteriophage Therapy for Infection-Linked Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rising tide of antibiotic-resistant human pathogens necessitates new treatments for bacterial infections that cause inflammation, especially those involving biofilms and disrupting native gut flora, and there is a need for effective bacteriophage therapy with reduced impurities.
Innovation Solution
Administering a purified bacteriophage composition that is essentially free of impurities to treat bacterial infections characterized by inflammation, and using gene expression profiling to determine therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bacteriophage therapy is used to treat antibiotic-resistant bacterial infections, then new treatment options are provided, but the presence of impurities in the composition may cause harmful effects
Solution Approach 1:
The patent applies purification methods to extract and remove impurities from the bacteriophage composition, retaining only the active bacteriophage components. This extraction process eliminates harmful substances while preserving the therapeutic efficacy of the bacteriophage therapy.
Solution Approach 2:
The patent changes the purity parameter of the bacteriophage composition by implementing multiple purification steps. This parameter change transforms the composition from a crude extract containing impurities to a highly purified product, thereby reducing harmful effects while maintaining therapeutic benefits.
2Object-affected harmful factors
If purified bacteriophage composition is administered to reduce inflammation, then inflammatory response is reduced, but the complexity of purification and formulation increases
Solution Approach 1:
The patent segments the purification process into multiple distinct steps including filtration, chromatography, and ultrafiltration. Each step targets specific types of impurities, making the complex purification process more manageable and systematic while achieving the desired reduction in inflammation.
Solution Approach 2:
The patent uses intermediary substances such as buffers, salts, and filtration membranes during the purification process. These intermediaries facilitate the separation and purification of bacteriophages from impurities, enabling effective inflammation reduction while managing the complexity through standardized intermediate materials.
3Measurement precision
If gene expression profiling is used to determine therapeutic efficacy, then treatment effectiveness is assessed, but the time and resources required for analysis increase
Solution Approach 1:
The patent performs preliminary gene expression profiling at baseline before bacteriophage treatment begins. This preliminary action establishes a reference point that enables rapid assessment of treatment efficacy by comparing post-treatment expressions against the pre-established baseline, reducing the time needed for efficacy determination.
Solution Approach 2:
The patent implements a feedback mechanism where gene expression profiles are analyzed and used to adjust subsequent treatment decisions. This feedback loop provides precise efficacy assessment while optimizing treatment timing, as the gene expression data directly informs whether continued treatment is necessary or if treatment can be discontinued.
Data Source
AI summary
The present invention relates to the treatment of bacterial infections and the reduction of inflammatory response using bacteriophage compositions. In an aspect, provided herein are methods of treating a bacterial infection characterized by inflammation in a subject, the method comprising administering to the subject a bacteriophage composition that is essentially free of impurities, wherein the composition reduces inflammation.